PAUL MONIZ: Open Payments
NPI 1154373017 · FARMINGTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,776 in 155 payments from 34 companies in 2025. Trend: 2023 $2,993 · 2024 $2,879 · 2025 $2,776
Food & beverage: $2,688Education: $87
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $512 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $266 |
| Otsuka America Pharmaceutical, Inc. | 12 | $214 |
| PFIZER INC. | 12 | $185 |
| Globus Medical, Inc. | 6 | $153 |
| Novo Nordisk Inc | 11 | $141 |
| Lilly USA, LLC | 5 | $114 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $114 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $112 |
| Sumitomo Pharma America, Inc. | 4 | $95 |
Products named: REXULTI, CAPLYTA, VRAYLAR, QULIPTA, Senza, UBRELVY, NURTEC ODT, MOUNJARO.
Industry payments across MO — which companies pay providers there.
